Clinical Aspects and Management of Levodopa-Induced Dyskinesia

In Parkinson's disease, one of the most troublesome dilemmas is the treatment of levodopa-induced dyskinesia. After a few years, chronic treatment with levodopa is associated with the development of dyskinesias. Strategies to delay or to reduce dyskinesias are based on the change of levodopa do...

Descripción completa

Detalles Bibliográficos
Autores principales: Tambasco, Nicola, Simoni, Simone, Marsili, Erica, Sacchini, Elisa, Murasecco, Donatella, Cardaioli, Gabriela, Rossi, Aroldo, Calabresi, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3372050/
https://www.ncbi.nlm.nih.gov/pubmed/22701811
http://dx.doi.org/10.1155/2012/745947
Descripción
Sumario:In Parkinson's disease, one of the most troublesome dilemmas is the treatment of levodopa-induced dyskinesia. After a few years, chronic treatment with levodopa is associated with the development of dyskinesias. Strategies to delay or to reduce dyskinesias are based on the change of levodopa dosing or the early use of dopamine agonists. Dopamine agonists with different pharmacological profile are available. Our paper was aimed to analyse the clinical impact and the management of dyskinesias with dopamine agonists.

Ejemplares similares